PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 77 filers reported holding PHATHOM PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 1.36 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,032,468 | +245.9% | 292,427 | +377.7% | 0.00% | – |
| Q2 2023 | $876,599 | -47.6% | 61,215 | -73.8% | 0.00% | – |
| Q1 2023 | $1,671,359 | +658.0% | 234,084 | +1091.1% | 0.00% | – |
| Q4 2022 | $220,507 | -78.6% | 19,653 | -78.9% | 0.00% | – |
| Q3 2022 | $1,030,000 | +0.4% | 93,000 | -23.4% | 0.00% | – |
| Q2 2022 | $1,026,000 | +33.6% | 121,412 | +115.3% | 0.00% | – |
| Q1 2022 | $768,000 | +239.8% | 56,400 | +391.9% | 0.00% | – |
| Q4 2021 | $226,000 | -80.3% | 11,466 | -67.9% | 0.00% | – |
| Q3 2021 | $1,146,000 | -57.9% | 35,710 | -55.6% | 0.00% | -100.0% |
| Q2 2021 | $2,721,000 | +747.7% | 80,374 | +841.0% | 0.00% | – |
| Q1 2021 | $321,000 | -20.0% | 8,541 | -29.3% | 0.00% | – |
| Q4 2020 | $401,000 | +63.0% | 12,076 | +79.8% | 0.00% | – |
| Q3 2020 | $246,000 | -20.1% | 6,716 | -43.8% | 0.00% | – |
| Q1 2020 | $308,000 | – | 11,948 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 2,067,861 | $40,675,000 | 10.18% |
| FRAZIER MANAGEMENT LLC | 5,827,415 | $114,625,000 | 8.82% |
| Abingworth LLP | 1,203,135 | $23,606,000 | 5.72% |
| RA Capital Management | 3,115,008 | $61,272,000 | 1.08% |
| Avidity Partners Management LP | 1,896,000 | $37,294,000 | 0.79% |
| StepStone Group LP | 422,085 | $8,302,000 | 0.47% |
| Summit Rock Advisors, LP | 34,100 | $671,000 | 0.40% |
| Parkman Healthcare Partners LLC | 77,481 | $1,524,000 | 0.34% |
| Rhenman & Partners Asset Management AB | 186,210 | $3,624,000 | 0.24% |
| Ikarian Capital, LLC | 74,560 | $1,467,000 | 0.22% |